Analysts expect Imperva Inc (NASDAQ:IMPV) to post $91.18 million in sales for the current quarter, Zacks Investment Research reports. Seven analysts have made estimates for Imperva’s earnings. The lowest sales estimate is $90.48 million and the highest is $92.00 million. Imperva posted sales of $78.40 million during the same quarter last year, which would indicate a positive year over year growth rate of 16.3%. The business is expected to announce its next earnings results after the market closes on Thursday, February 8th.

On average, analysts expect that Imperva will report full-year sales of $91.18 million for the current fiscal year, with estimates ranging from $321.00 million to $322.64 million. For the next year, analysts expect that the firm will post sales of $376.91 million per share, with estimates ranging from $372.00 million to $383.00 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side analysts that follow Imperva.

Several research analysts have recently weighed in on the stock. BidaskClub upgraded shares of Imperva from a “hold” rating to a “buy” rating in a research note on Wednesday. Zacks Investment Research lowered shares of Imperva from a “buy” rating to a “hold” rating in a research note on Wednesday, January 10th. JPMorgan Chase & Co. lowered shares of Imperva from a “neutral” rating to an “underweight” rating and set a $45.00 price objective on the stock. in a research note on Tuesday, December 12th. Morgan Stanley restated an “underweight” rating and set a $39.00 price objective on shares of Imperva in a research note on Thursday, November 9th. Finally, Oppenheimer restated a “buy” rating and set a $55.00 price objective on shares of Imperva in a research note on Thursday, November 9th. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating and ten have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $51.86.

Imperva (NASDAQ:IMPV) opened at $43.25 on Thursday. Imperva has a 52 week low of $37.17 and a 52 week high of $52.40.

Several hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its holdings in shares of Imperva by 4.3% during the 2nd quarter. Vanguard Group Inc. now owns 2,439,240 shares of the software maker’s stock worth $116,718,000 after buying an additional 99,799 shares during the period. BlackRock Inc. boosted its holdings in Imperva by 11.3% in the 2nd quarter. BlackRock Inc. now owns 2,124,043 shares of the software maker’s stock valued at $101,635,000 after purchasing an additional 215,170 shares during the period. Eagle Asset Management Inc. boosted its holdings in Imperva by 1.2% in the 3rd quarter. Eagle Asset Management Inc. now owns 1,294,651 shares of the software maker’s stock valued at $55,928,000 after purchasing an additional 14,803 shares during the period. Alyeska Investment Group L.P. boosted its holdings in Imperva by 89.3% in the 3rd quarter. Alyeska Investment Group L.P. now owns 907,615 shares of the software maker’s stock valued at $39,390,000 after purchasing an additional 428,163 shares during the period. Finally, Emerald Advisers Inc. PA boosted its holdings in Imperva by 15.8% in the 3rd quarter. Emerald Advisers Inc. PA now owns 657,005 shares of the software maker’s stock valued at $28,514,000 after purchasing an additional 89,463 shares during the period. 96.61% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: This news story was reported by Daily Political and is the property of of Daily Political. If you are reading this news story on another publication, it was illegally stolen and republished in violation of United States & international copyright & trademark law. The correct version of this news story can be viewed at https://www.dailypolitical.com/2018/02/08/imperva-inc-impv-expected-to-post-quarterly-sales-of-91-18-million.html.

About Imperva

Imperva, Inc provides cyber-security solutions that protect business-critical data and applications whether in the cloud or on premises. The Company is engaged in the development, marketing, sales, service and support of cyber-security solutions. The Company’s products include its Imperva SecureSphere Paltform, Imperva CounterBreach and Imperva Camouflage for enterprise data centers, and Imperva Incapsula offering for cloud-based security services.

Get a free copy of the Zacks research report on Imperva (IMPV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Imperva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imperva and related companies with MarketBeat.com's FREE daily email newsletter.